Pacira BioSciences is a holding company. Through its subsidiaries, Co. is focused on non-opioid pain management. Co. has three commercialized non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesic approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, corticosteroid injection indicated for the management of OA knee pain; and iovera°®, a handheld device for delivering immediate, long-acting, drug-free pain control using controlled doses of cold temperature to a targeted nerve. We show 54 historical shares outstanding datapoints in our coverage of PCRX's shares outstanding history.
Understanding the changing numbers of PCRX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like PCRX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching PCRX by allowing them to research PCRX shares outstanding history
as well as any other stock in our coverage universe. |
Free PCRX Email Alerts:
Video: Shares Outstanding Importance
